Related Experiment Video
Updated: Apr 16, 2026

Detection of Polyfunctional T Cells in Children Vaccinated with Japanese Encephalitis Vaccine via the Flow Cytometry Technique
Published on: September 23, 2022
Five year follow-up after primary vaccination against tick-borne encephalitis in children
Christoph Wittermann1, Allen Izu2, Eckhardt Petri3
1Am Bachlanger 3, D-82362 Weilheim, Germany.
Insights
Antibody persistence after tick-borne encephalitis (TBE) vaccination in children shows Encepur® Children provides protective levels for 5 years. This supports extending the TBE vaccine booster interval to 5 years for children who received the full Encepur® Children primary series.
Area of Science:
- Pediatric infectious diseases
- Vaccinology
- Immunology
Background:
- Current tick-borne encephalitis (TBE) vaccine booster recommendations for children suggest a 3-year interval after primary immunization.
- This interval may be insufficient when different TBE vaccines are used interchangeably during primary vaccination.
Purpose of the Study:
- To evaluate TBE antibody persistence in children after primary vaccination with different TBE vaccine schedules.
- To inform optimal timing for the first TBE vaccine booster dose.
Main Methods:
- Antibody persistence was assessed in children (5-15 years) vaccinated with either Encepur® Children (full series) or a mixed series (FSME-IMMUN® followed by Encepur® Children).
- Immunogenicity was measured using neutralization (NT) and Enzyme Linked Immunosorbent Assay (ELISA) up to 5 years post-vaccination.
Main Results:
- Children fully vaccinated with Encepur® Children maintained protective NT titers (≥10) in 98-100% up to 5 years post-vaccination.
- In contrast, only 65-70% of children receiving a mixed vaccine series had protective titers at 3 years.
- The mixed vaccine groups were discontinued due to lower long-term antibody persistence.
Conclusions:
- Full primary vaccination with Encepur® Children elicits a robust antibody response lasting at least 5 years.
- The findings support extending the recommended interval for the first TBE vaccine booster dose from 3 to 5 years for children completing the Encepur® Children primary series.
Background:
A first tick-borne encephalitis (TBE) vaccine booster in children is currently suggested 3 years after completing either a conventional (doses on Days 0, 28 and 300) or accelerated conventional (doses on Days 0, 14 and 300) TBE immunization schedule. This recommendation, however, may not be appropriate in cases where different TBE vaccines have been used interchangeably during the primary immunization series.
Methods:
To provide robust data to better inform such recommendations, TBE antibody persistence was evaluated after 3-5 years in four groups of children (aged 5-15 years): two groups previously primed with three doses of Encepur(®) Children (conventional/accelerated conventional schedule); and two groups previously primed with two doses of FSME-IMMUN(®) followed by a third dose of Encepur(®) Children (conventional/accelerated conventional schedule). Immunogenicity was evaluated using neutralization (NT) assays based on both vaccine antigens as well as on the Enzyme Linked Immunosorbent Assay (ELISA).
Results:
In the two Encepur(®) Children groups (full series), protective NT titers of ≥10 were detected in 98-100% of children up to 5 years after their last primary vaccination, irrespective of schedule. In contrast, only 65-70% subjects in the FSME-IMMUN(®) Junior groups (mixed series) displayed NT titers ≥10 after 3 years. Thus, due to lower probability of achieving/maintaining long-term protective antibody levels (recently defined by the World Health Organization as an NT titer ≥10) after this time point, both FSME-IMMUN Junior groups were discontinued.
Conclusion:
A strong antibody response persists for at least 5 years after full primary vaccination with Encepur(®) Children. The study thus provides support for extending the time interval for a first booster dose after primary vaccination (conventional/accelerated conventional schedule) with Encepur(®) Children from 3 to 5 years.
More Related Videos
06:22Standardization of Transfer across Labs between Flow Cytometers for Detection of Lymphocytes in Japanese Encephalitis Vaccinated Children
Published on: February 10, 2023
05:33A Model for Epilepsy of Infectious Etiology using Theiler's Murine Encephalomyelitis Virus
Published on: June 23, 2022
Related Concept Videos
Arboviral Encephalitis
Vaccinations